NANO Nordic Nanovector ASA

Nordic Nanovector ASA: Issuance of Restricted Stock Units (RSUs) to the New Board Member Joanna Horobin

Nordic Nanovector (OSE: NANO) (OSE: NANOO)

Reference is made to the extraordinary general meeting of Nordic Nanovector ASA's (the "Company") on 12 October 2016 (the "EGM") where Joanna Horobin was elected a new board member.

At the ordinary general meeting of the Company the board of directors was authorised to issue restricted stock units ("RSUs") to the board members. The RSUs are non-transferable and each RSU gives the right and obligation to acquire one share in the Company at a price of NOK 0.20 per share (corresponding to the nominal value of the shares) subject to satisfaction of the applicable vesting conditions.

Joanna Horobin has resolved to receive her full board remuneration, as determined by the Company's annual general meeting in 2016, in the form of RSU's and the board of directors has resolved to issue 2,678 RSU's to Joanna Horobin. The number of RSU's is calculated on the basis of a board remuneration of NOK 144,000 divided by the market price of the Company's shares calculated as the average share price for the 10 trading days prior to the EGM being NOK 53.77 per share. Joanna Horobin does not hold any other shares in the Company.

This information is subject to duty of disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

EN
20/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nordic Nanovector ASA

Patrik Ling
  • Patrik Ling

Nordic Nanovector (No_rec, TP: NOK) - Discontinuing coverage

We have discontinued coverage of Nordic Nanovector due to a reallocation of analyst resources. Our last published recommendation, target price and estimates should no longer be relied upon.

Patrik Ling
  • Patrik Ling

Nordic Nanovector (No_rec, TP: NOK) - Proposed merger with APIM Therap...

Nordic Nanovector has concluded its strategic review, and the outcome is a proposed merger with the unlisted Norwegian company APIM Therapeutics. Under the proposed terms of the merger, the owners of APIM Therapeutics are set to have c76% of the combined entity, while Nordic Nanovector’s owners would have c24%. An EGM has been scheduled for 1 December or thereabouts and, if approved, the transaction should close in late Q4. We have removed our recommendation and target price following the strate...

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach

Nordic Nanovector - Terminating coverage

ABGSC ceases coverage of Nordic Nanovector SELL is our final recommendation NOK 1.5 is our final target price

Patrik Ling
  • Patrik Ling

Nordic Nanovector (Hold, TP: NOK1.60) - Limited visibility on strategi...

The decision to terminate the PARADIGME phase IIb trial in Q2 clearly has major repercussions for Nordic Nanovector given it was the most mature development project in its pipeline. Operations have already been drastically downsized, with c70% of personnel laid off. No new data or real explanation for the weak efficacy in the trial was given, and with limited value in the early-stage pipeline in our view, we value the company at its end-2022e cash position. We reiterate our HOLD and NOK1.6 targe...

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach

Nordic Nanovector - Q2 report

Company restructure leads to 70% staff reduction NOK ~185m in study closing costs leaves NOK ~100m Webcast today at 8:30 am CET

ResearchPool Subscriptions

Get the most out of your insights

Get in touch